Laddar...
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody–drug conjugate (ADC) that recently gained regulatory approval for the treatment of relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least four prior therapies including a...
Sparad:
| I publikationen: | Ther Adv Hematol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7739070/ https://ncbi.nlm.nih.gov/pubmed/33403093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720979813 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|